| Autor: |
A, Batalla, R, Fernández-Torres, L, Rodríguez-Pazos, B, Monteagudo, R, Pardavila-Riveiro, R, Rodríguez-Lojo, Á, Zulaica, M, Cabanillas, E, Fonseca, Á, León, L, Fernández-Díaz, T, Abalde, L, Salgado-Boquete, F, Valdés, M J, Seoane-Pose, H, Vázquez-Veiga, I, Suárez-Conde, J, Álvarez-López, Á, Flórez |
| Rok vydání: |
2018 |
| Předmět: |
|
| Zdroj: |
Actas dermo-sifiliograficas. 109(8) |
| ISSN: |
2173-5778 |
| Popis: |
Studies on the use of systemic therapy for psoriasis in pediatric patients are scarce. The main aim of this study was to describe the systemic treatments used for moderate to severe psoriasis in pediatric clinical settings. The second aim was to describe the effectiveness and safety of these treatments.Descriptive, cross-sectional, multicenter study of patients under 18 years of age with moderate to severe psoriasis who were being treated or had been treated with a systemic drug (conventional or biologic) or phototherapy. We recorded demographic and clinical information, treatments received, tolerance, adverse effects, and response to treatment.Data were collected for 40 patients (60% female; mean age, 13 years) who had received 63 treatments in total. The most common first treatment (n=40) was phototherapy (administered to 68% of patients), followed by acitretin (15%). The most common treatments overall (n=63) were phototherapy (57%) and methotrexate (16%). At week 12 (evaluation of systemic treatment and phototherapy), 66% of the patients were classified as good responders and 22% as partial responders. The respective rates for week 24 (evaluation of systemic treatment only) were 36% and 32%. The treatments were well tolerated (97%) and adverse effects were reported in just 11% of cases. There were no treatment discontinuations because of adverse effects.Phototherapy, followed by methotrexate, was the most common treatment for moderate to severe psoriasis in this series of patients under 18 years. The treatments showed a favorable safety profile and were associated with a good response rate of 66% at week 12 (systemic treatment and phototherapy) and 36% at week 24 (systemic treatment only). |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect